Palisade Bio Secures Japanese Patent for PALI-2108 IBD Treatment

Palisade Bio (PALI) receives Japan patent for PALI-2108, a targeted PDE4 inhibitor for ulcerative colitis and Crohn's disease, with Phase 2 trials planned for 2026.